Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries
Cosmos Health (NASDAQ:COSM) has secured a distribution agreement with Virax Biolabs for Avian Influenza Virus (AIV) Real-Time PCR Kits. The agreement grants exclusive distribution rights in Greece and Cyprus, along with non-exclusive rights in 12 European countries and 2 GCC nations (Oman and Bahrain).
The RT-PCR tests detect RNA from AIV, including H5, H7, and H9 subtypes, particularly the H5N1 strain. These kits enable healthcare professionals to quickly identify infections in individuals exposed to infected livestock or high-risk environments. Under the agreement, Cosmos Health will handle import, sales, and distribution, while Virax will manage regulatory compliance and documentation for product approvals.
The partnership aims to enhance global preparedness against avian influenza outbreaks by providing specialized testing capabilities that can differentiate between various strains, supporting rapid response and intervention in healthcare systems.
Cosmos Health (NASDAQ:COSM) ha ottenuto un accordo di distribuzione con Virax Biolabs per i Kit PCR in tempo reale per il Virus dell'Influenza Aviaria (AIV). L'accordo conferisce diritti di distribuzione esclusiva in Grecia e Cipro, insieme a diritti non esclusivi in 12 paesi europei e 2 nazioni del GCC (Oman e Bahrein).
I test RT-PCR rilevano l'RNA dell'AIV, inclusi i sottotipi H5, H7 e H9, in particolare il ceppo H5N1. Questi kit consentono ai professionisti sanitari di identificare rapidamente le infezioni in individui esposti a bestiame infetto o ambienti ad alto rischio. Sotto l'accordo, Cosmos Health si occuperà di importazione, vendite e distribuzione, mentre Virax gestirà la conformità normativa e la documentazione per le approvazioni dei prodotti.
La partnership mira a migliorare la preparazione globale contro le epidemie di influenza aviaria fornendo capacità di testing specializzate che possono differenziare tra vari ceppi, supportando una risposta rapida e intervento nei sistemi sanitari.
Cosmos Health (NASDAQ:COSM) ha asegurado un acuerdo de distribución con Virax Biolabs para Kits de RT-PCR del Virus de la Influenza Aviar (AIV). El acuerdo otorga derechos de distribución exclusivos en Grecia y Chipre, junto con derechos no exclusivos en 12 países europeos y 2 naciones del CCG (Omán y Baréin).
Las pruebas de RT-PCR detectan el ARN del AIV, incluyendo los subtipos H5, H7 y H9, en particular la cepa H5N1. Estos kits permiten a los profesionales de la salud identificar rápidamente infecciones en individuos expuestos a ganado infectado o entornos de alto riesgo. Según el acuerdo, Cosmos Health se encargará de la importación, ventas y distribución, mientras que Virax se encargará del cumplimiento normativo y la documentación para las aprobaciones de productos.
La asociación tiene como objetivo mejorar la preparación global contra los brotes de influenza aviar al proporcionar capacidades de pruebas especializadas que pueden diferenciar entre varias cepas, apoyando una respuesta rápida e intervención en los sistemas de salud.
코스모스 헬스 (NASDAQ:COSM)는 바이락스 바이오랩스와 함께 조류 인플루엔자 바이러스 (AIV) 실시간 PCR 키트에 대한 배급 계약을 체결했습니다. 이 계약은 그리스와 키프로스에서의 독점 배급 권한을 부여하며, 12개 유럽 국가와 2개 GCC 국가(오만과 바레인)에서 비독점 권한도 포함됩니다.
RT-PCR 테스트는 H5, H7, H9 아형을 포함한 AIV의 RNA를 탐지하며, 특히 H5N1 변종에 대해 검사합니다. 이 키트는 의료 전문가들이 감염된 가축이나 고위험 환경에 노출된 개인에서 감염을 신속하게 식별할 수 있게 해줍니다. 계약에 따라 코스모스 헬스는 수입, 판매 및 유통을 담당하고, 바이락스는 제품 승인에 대한 규제 준수 및 문서를 관리합니다.
이 파트너십은 다양한 변종을 구별할 수 있는 전문 테스트 기능을 제공하여 조류 인플루엔자 발생에 대한 전 세계적 대비 태세를 향상하고, 의료 시스템에서의 신속한 대응과 개입을 지원하는 것을 목표로 합니다.
Cosmos Health (NASDAQ:COSM) a conclu un accord de distribution avec Virax Biolabs pour les kits PCR en temps réel concernant le virus de l'influenza aviaire (AIV). L'accord accorde des droits de distribution exclusifs en Grèce et à Chypre, ainsi que des droits non exclusifs dans 12 pays européens et 2 nations du CCG (Oman et Bahreïn).
Les tests RT-PCR détectent l'ARN de l'AIV, y compris les sous-types H5, H7 et H9, en particulier la souche H5N1. Ces kits permettent aux professionnels de la santé d'identifier rapidement les infections chez les individus exposés au bétail infecté ou à des environnements à haut risque. En vertu de cet accord, Cosmos Health s'occupera de l'importation, des ventes et de la distribution, tandis que Virax gérera la conformité réglementaire et la documentation pour les approbations de produits.
Le partenariat vise à améliorer la préparation mondiale face aux épidémies de grippe aviaire en fournissant des capacités de tests spécialisées capables de différencier entre plusieurs souches, soutenant ainsi une réponse rapide et une intervention dans les systèmes de santé.
Cosmos Health (NASDAQ:COSM) hat einen Vertriebsvertrag mit Virax Biolabs für Real-Time PCR-Kits zum Nachweis des Aviären Influenza-Virus (AIV) gesichert. Der Vertrag gewährt exklusive Vertriebsrechte in Griechenland und Zypern, sowie nicht-exklusive Rechte in 12 europäischen Ländern und 2 GCC-Nationen (Oman und Bahrain).
Die RT-PCR-Tests erkennen RNA von AIV, einschließlich der Subtypen H5, H7 und H9, insbesondere des Stamm H5N1. Diese Kits ermöglichen es Gesundheitsfachkräften, Infektionen bei Personen, die Kontakt mit infiziertem Vieh oder hochriskanten Umgebungen hatten, schnell zu identifizieren. Im Rahmen des Vertrages wird Cosmos Health für Import, Verkauf und Vertrieb verantwortlich sein, während Virax die regulatorische Konformität und die Dokumentation für Produktgenehmigungen verwaltet.
Die Partnerschaft zielt darauf ab, die globale Vorbereitung auf Ausbrüche der Vogelgrippe zu verbessern, indem spezialisierte Testmöglichkeiten bereitgestellt werden, die zwischen verschiedenen Stämmen unterscheiden können, und damit eine schnelle Reaktion und Intervention in den Gesundheitssystemen unterstützen.
- Secured exclusive distribution rights for AIV PCR kits in Greece and Cyprus
- Gained non-exclusive distribution rights in 12 additional European countries and 2 GCC nations
- Partnership expands product portfolio in diagnostic testing market
- None.
Insights
The distribution agreement for Virax's AIV PCR kits represents a strategic expansion into critical diagnostic testing markets. The exclusive rights for Greece and Cyprus, combined with non-exclusive access to major European and GCC markets, positions Cosmos Health to capitalize on the growing demand for advanced viral detection systems. The H5N1 detection capability is particularly valuable given the strain's 80% mortality rate in human cases.
The PCR kits' ability to detect multiple AIV subtypes (H5, H7, H9) significantly enhances their market value and clinical utility. For context, traditional testing methods can take 3-5 days, while these RT-PCR tests can deliver results in hours, enabling faster intervention and containment strategies. This timing advantage is important for managing potential outbreaks.
However, the revenue impact may be initially modest given COSM's small market cap of
This partnership significantly expands COSM's product portfolio in the high-margin diagnostics sector. The distribution rights cover 14 strategic markets, including major European economies and emerging GCC markets. The timing is opportune, as global health organizations are increasingly focusing on zoonotic disease surveillance.
The deal's structure - exclusive rights in core markets and non-exclusive rights in larger territories - creates a balanced market approach. This allows COSM to build strong market presence in Greece and Cyprus while testing demand in broader markets with minimal territorial restrictions.
From a market perspective, the agreement enhances COSM's revenue diversification strategy, moving beyond traditional healthcare products into advanced diagnostics. This could potentially improve the company's market position and valuation metrics, though initial revenue impact may be gradual given the specialized nature of the product and current market cap constraints.
CHICAGO, IL / ACCESSWIRE / January 13, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into a distribution agreement with Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax") to distribute Virax-branded Avian Influenza Virus ("AIV") Real-Time PCR Kits across various major European markets and certain Gulf Cooperation Council (GCC) countries.
Specifically, Cosmos Health gains exclusive rights to distribute these kits in Greece and Cyprus, as well as non-exclusive rights in select European countries, including France, Portugal, Spain, The Netherlands, Belgium, Sweden, Finland, Denmark, Norway, Germany, Switzerland, and Austria. The agreement also grants non-exclusive distribution rights in certain Gulf Cooperation Council (GCC) countries, namely Oman and Bahrain.
These specialized RT-PCR tests reliably detect ribonucleic acid (RNA) from AIV, including the H5, H7, and H9 subtypes, such as the globally concerning H5N1 strain. By enabling healthcare professionals to quickly identify infections, the kits play a crucial role in screening individuals exposed to infected livestock or high-risk environments, supporting effective public health responses.
Under the agreement, Cosmos Health is authorized to import, sell, and distribute ViraxClear-branded kits within the agreed territories, while Virax will oversee regulatory compliance and provide the necessary documentation to support product registration and approval in these regions.
Greg Siokas, CEO of Cosmos Health, stated: "We are pleased to expand our collaboration with Virax and bring additional life-saving diagnostics to the forefront of healthcare. As avian influenza outbreaks continue to cause concern globally, our goal is to equip professionals, governments, and public health authorities with cutting-edge tools to detect and contain this potentially dangerous virus. Our partnership with Virax aligns with our dedication to delivering innovative healthcare solutions around the world."
James Foster, CEO of Virax, commented: "This agreement underscores our commitment to broadening the reach of our diagnostic platforms and ensuring that healthcare providers have timely access to next-generation testing capabilities. By leveraging Cosmos Health's established distribution network and expertise, we anticipate that these Avian Influenza Virus detection kits will reach key markets quickly, allowing for rapid response and intervention."
According to public health data, human infections with AIV have occurred in several regions, largely following exposure to infected poultry or contaminated environments. By supplying specialized Avian Influenza A Virus test kits that accurately differentiate among the various strains, Cosmos Health and Virax aim to enhance global preparedness, reduce the risk of transmission, and support healthcare systems in effectively monitoring and containing potential outbreaks.
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, as well as LinkedIn and X.
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.
For more information, please visit www.viraxbiolabs.com.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
SOURCE: Cosmos Health Inc.
View the original press release on accesswire.com
FAQ
What territories are covered by COSM's exclusive distribution rights for AIV PCR kits?
Which European countries are included in COSM's non-exclusive distribution agreement?
What types of AIV strains can the PCR kits distributed by COSM detect?
What are COSM's responsibilities under the Virax distribution agreement?
Which GCC countries are included in COSM's distribution agreement?
